In addition, we demonstrate that PF-06747143 monotherapy treatment potently reduces leukemia burden in PB, BM, and spleen in AML PDX models expressing low and high levels of CXCR4 and this is associated with increased survival. Here, CXCR4 is linked to leukemia.